Recent Updates
Recently added Catalysts
NTLA

Intellia Therapeutics to Present at Leerink Partners 6th Annual Global Healthcare Conference

Key Takeaway: CAMBRIDGE, Mass., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that Chief Executive Officer and Founder Nessan

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+76%
120-day peak, hindsight
Typical move
9.6%
average across 8 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
NTLA-2002
Phase 3 · Hereditary Angioedema

Full Press Release Details

CAMBRIDGE, Mass., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that Chief Executive Officer and Founder Nessan Bermingham, Ph.D., will present at the Leerink Partners 6th Annual Global Healthcare Conference, Wednesday, February 15, 2017.
Details of the presentation are as follows:
Date: Wednesday, February 15, 2017
Location: Lotte New York Palace, New York, New York
Time: The presentation will be at 10:00 am ET
Webcast: Available live during the presentation, and through replay on the company’s website immediately following. To participate in the webcast go to Leerink registration.
About Intellia Therapeutics
Last updated: Feb 1, 2017